🇺🇸 FDA
Pipeline program

Dupixent®

DAIT ITN084AD

Phase 2 mab completed

Quick answer

Dupixent® for Allergic Rhinoconjunctivitis is a Phase 2 program (mab) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Allergic Rhinoconjunctivitis
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials